# Operant behavior is reliably impaired in a mouse model of Angelman syndrome

**Authors:** Caleigh D. Guoynes, Devante D. Kerr, Zahraa S. Hotait, Joseph K. Tanas, Michael S. Sidorov

PMC · DOI: 10.21203/rs.3.rs-9043922/v1 · 2026-03-20

## TL;DR

A mouse model of Angelman syndrome shows consistent learning impairments in operant tasks, suggesting these tasks can help evaluate potential treatments.

## Contribution

Operant behavior testing is shown to reliably detect cognitive impairments in Angelman syndrome mouse models across sexes.

## Key findings

- Ube3am−/p+ mice showed impairments in operant task acquisition and extinction phases.
- Operant testing improved genotype clustering in behavioral assessments.
- Operant tasks are a reliable method to quantify learning impairments in Angelman syndrome models.

## Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder characterized by cognitive impairment, absent speech, seizures, motor and sleep impairments, and caused by loss of function of the maternal copy of the UBE3A gene. Modeling the AS phenotype in preclinical models across behavioral domains is critical for testing of new therapeutics. Our previous work reported behavioral phenotypes in male Ube3am−/p+ (AS model) mice on a cognitive-like operant extinction task. Here, we evaluated operant task performance in male and female Ube3am−/p+ mice across two cohorts, and correlated operant performance with performance on a battery of other widely used behavioral tests for Ube3a mutants. Ube3am−/p+ mice showed impairments in both the acquisition and extinction phases of operant testing that were not sex-specific. Inclusion of operant testing in the existing Ube3am−/p+ behavioral battery was feasible and improved clustering of genotypes in principal component space. Overall, operant acquisition and extinction testing is a reliable approach to quantify cognitive-like learning impairments in Ube3am−/p+ mice. Operant testing should be considered as part of a broad toolbox for evaluating the effectiveness of AS treatments preclinically.

## Linked entities

- **Genes:** UBE3A (ubiquitin protein ligase E3A) [NCBI Gene 7337]
- **Diseases:** Angelman syndrome (MONDO:0007113)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ube3a (ubiquitin protein ligase E3A) [NCBI Gene 22215] {aka 4732496B02, 5830462N02Rik, A130086L21Rik, Hpve6a}
- **Diseases:** absent speech (MESH:D013064), seizures (MESH:D012640), AS (MESH:D017204), neurodevelopmental disorder (MESH:D002658), learning impairments (MESH:D007859), motor and sleep impairments (MESH:D012893), cognitive impairment (MESH:D003072)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13015589/full.md

---
Source: https://tomesphere.com/paper/PMC13015589